Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics, a clinical-stage company developing genetic medicines for cardiovascular disease, has announced the granting of equity awards to five new employees on September 30, 2024. These awards, made under the company's 2024 Inducement Stock Incentive Plan, are in accordance with Nasdaq Listing Rule 5635(c)(4) and serve as an inducement for employment.
The equity awards consist of an aggregate of 33,280 restricted stock units (RSUs). These RSUs will vest in equal annual installments over four years, starting from October 1, 2024, contingent on the employees' continued service with Verve Therapeutics.
Verve Therapeutics, un'azienda in fase clinica che sviluppa terapie genetiche per le malattie cardiovascolari, ha annunciato il conferimento di premi azionari a cinque nuovi dipendenti il 30 settembre 2024. Questi premi, attribuiti secondo il Piano di Incentivazione Azionaria 2024 dell'azienda, sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) e servono come incentivo per l'assunzione.
I premi azionari consistono in un totale di 33.280 unità azionarie riservate (RSU). Queste RSU verranno accreditate in rate annuali uguali per quattro anni, a partire dal 1 ottobre 2024, a condizione che i dipendenti continuino a lavorare con Verve Therapeutics.
Verve Therapeutics, una empresa en etapa clínica que desarrolla medicamentos genéticos para enfermedades cardiovasculares, ha anunciado la concesión de premios en acciones a cinco nuevos empleados el 30 de septiembre de 2024. Estos premios, otorgados bajo el Plan de Incentivos de Acciones 2024 de la empresa, están de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4) y sirven como un incentivo para el empleo.
Los premios de acciones consisten en un total de 33.280 unidades de acciones restringidas (RSUs). Estas RSUs se consolidarán en cuotas anuales iguales durante cuatro años, comenzando el 1 de octubre de 2024, sujeto a la continuación del servicio de los empleados en Verve Therapeutics.
Verve Therapeutics는 심혈관 질환을 위한 유전자 치료제를 개발하는 임상 단계 회사로, 2024년 9월 30일 5명의 신입 직원에게 주식 보상을 부여한다고 발표했습니다. 이 보상은 회사의 2024 유인 주식 인센티브 계획에 따라 이루어지며, Nasdaq 상장 규칙 5635(c)(4)에 부합하며 고용을 위한 유인 역할을 합니다.
주식 보상은 총 33,280개의 제한 주식 단위(RSU)로 구성됩니다. 이 RSU는 2024년 10월 1일부터 시작하여 4년에 걸쳐 매년 동일한 금액으로 분배되며, Verve Therapeutics에서 계속 근무하는 것이 조건입니다.
Verve Therapeutics, une entreprise en phase clinique qui développe des médicaments génétiques pour les maladies cardiovasculaires, a annoncé l'octroi de primes en actions à cinq nouveaux employés le 30 septembre 2024. Ces primes, attribuées dans le cadre du Plan d'Incitation à l'Action 2024 de l'entreprise, sont conformes à la Règle de Cotation Nasdaq 5635(c)(4) et servent d'incitation à l'embauche.
Les primes en actions consistent en un total de 33 280 unités d'actions restreintes (RSU). Ces RSU seront acquises en versements annuels égaux sur quatre ans, à compter du 1er octobre 2024, sous réserve de la poursuite du service des employés chez Verve Therapeutics.
Verve Therapeutics, ein Unternehmen in der klinischen Phase, das genetische Medikamente für Herz-Kreislauf-Erkrankungen entwickelt, hat am 30. September 2024 die Gewährung von Aktienprämien an fünf neue Mitarbeiter bekannt gegeben. Diese Prämien, die im Rahmen des Aktienanreizplans 2024 des Unternehmens vergeben werden, entsprechen der Nasdaq-Listing-Regel 5635(c)(4) und dienen als Anreiz für eine Einstellung.
Die Aktienprämien bestehen aus insgesamt 33.280 eingeschränkten Aktieneinheiten (RSUs). Diese RSUs werden in gleiche jährliche Raten über vier Jahre hinweg verteilt, beginnend am 1. Oktober 2024, und sind an die fortdauernde Beschäftigung der Mitarbeiter bei Verve Therapeutics gebunden.
- Verve Therapeutics is attracting new talent with equity incentives
- The company is aligning employee interests with shareholder interests through RSU grants
- None.
BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on September 30, 2024, the company granted equity awards to five new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received an aggregate of 33,280 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of October 1, 2024, subject to each such employee’s continued service with the company on each such vesting date.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic management to single-course gene editing medicines. The company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally-tolerated standard of care therapies, and for homozygous familial hypercholesterolemia (HoFH). For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
FAQ
How many new employees received equity awards from Verve Therapeutics (VERV) on September 30, 2024?
What type of equity awards did Verve Therapeutics (VERV) grant to new employees?
What is the vesting schedule for the RSUs granted by Verve Therapeutics (VERV) on September 30, 2024?
Under which plan did Verve Therapeutics (VERV) grant the equity awards to new employees?
